# MOCS2

## Overview
The MOCS2 gene encodes the molybdenum cofactor synthesis 2 protein, which plays a pivotal role in the biosynthesis of the molybdenum cofactor (MoCo), a critical component for the activity of various molybdoenzymes. These enzymes are essential for numerous metabolic processes, including the catabolism of sulfur-containing amino acids and purine degradation. The MOCS2 gene is characterized by its bicistronic structure, producing two distinct proteins, MOCS2A and MOCS2B, from a single transcript. These proteins form part of the molybdopterin synthase complex, a key player in the conversion of precursor Z to molybdopterin, an essential step in MoCo biosynthesis (Reiss2003Mutations; JezelaStanek2020Proteins). Mutations in MOCS2 can lead to molybdenum cofactor deficiency type B, a severe metabolic disorder with significant neurological implications (Arican2019The). Understanding the function and interactions of the MOCS2 gene and its encoded proteins is crucial for elucidating the molecular mechanisms underlying related metabolic disorders and developing potential therapeutic strategies.

## Structure
The MOCS2 gene encodes the molybdopterin synthase complex, which is crucial for molybdenum cofactor biosynthesis. This complex is a dimer composed of two heterodimers, each consisting of a sulfur carrier subunit and a catalytic subunit (JezelaStanek2020Proteins). The MOCS2 gene has a bicistronic structure with two overlapping open reading frames, MOCS2A and MOCS2B, which are translated into two different proteins from a single transcript without alternative splicing (Reiss2003Mutations).

The catalytic subunit of the molybdopterin synthase complex includes a crucial region at the C-terminus, where residues Leu158 and Lys159 are located. These residues are essential for binding the sulfur carrier subunit and precursor Z, a key step in the biosynthesis process (JezelaStanek2020Proteins). The deletion of these residues, as seen in the c.472_477del variant, can impact the protein's folding and binding affinity, potentially altering the formation of the active complex (JezelaStanek2020Proteins).

The MOCS2B subunit's C-terminus is particularly important for maintaining functional integrity, as mutations in this region can disrupt the formation of the molybdopterin synthase complex (Leimkühler2005Ten).

## Function
The MOCS2 gene is involved in the biosynthesis of the molybdenum cofactor (MoCo), which is essential for the activity of molybdoenzymes. These enzymes, including sulfite oxidase, xanthine dehydrogenase, and aldehyde oxidase, play crucial roles in various metabolic processes such as the catabolism of sulfur-containing amino acids and purine degradation (Stoilov2002Defects). MOCS2 encodes proteins that participate in the early steps of MoCo biosynthesis, primarily in the cytoplasm, facilitating the proper functioning of these enzymes. The molybdenum cofactor is vital for the catalytic activity of molybdoenzymes, which are involved in critical biochemical pathways in human cells. Deficiencies in these enzymes due to mutations in the MOCS2 gene can lead to metabolic disorders, highlighting the gene's importance in maintaining normal cellular and organismal functions. The proper functioning of MOCS2 is crucial for preventing diseases such as molybdenum cofactor deficiency (MoCoD), an inherited autosomal recessive disorder that results from a deficiency in molybdoenzymes (Stoilov2002Defects). Understanding the role of MOCS2 in MoCo biosynthesis is essential for developing therapeutic strategies for related metabolic disorders.

## Clinical Significance
Mutations in the MOCS2 gene are associated with molybdenum cofactor deficiency type B (MOCODB), a rare autosomal recessive metabolic disorder. This condition is characterized by severe neurological symptoms, including intractable seizures, developmental delays, and distinctive craniofacial features. The deficiency results from impaired activity of molybdenum cofactor-dependent enzymes, such as sulfite oxidase and xanthine dehydrogenase, leading to the accumulation of toxic sulfite levels and subsequent neurological damage (Arican2019The; JezelaStanek2020Proteins).

Patients with MOCS2 mutations often present with early infantile epileptic encephalopathy, specifically Ohtahara syndrome, which is marked by myoclonic seizures and severe cognitive and motor delays (Tofilo2023Live). The mutations can include various types, such as deletions, missense, and nonsense mutations, which affect the gene's function and lead to a range of clinical outcomes (Hinderhofer2017Critical; Reiss2003Mutations).

The severity of the condition can vary depending on the specific mutations present. Severe genotypes often involve nonsense or frameshift mutations, leading to worse clinical outcomes and lower survival rates (Hinderhofer2017Critical). Early diagnosis and genetic analysis are crucial for providing adequate genetic counseling, although effective therapies are currently lacking (Arican2019The).

## Interactions
MOCS2 is involved in several protein interactions essential for its function in molybdenum cofactor (Moco) biosynthesis and other cellular processes. MOCS2 consists of two subunits, MOCS2A and MOCS2B, which form part of the molybdopterin synthase complex. This complex is crucial for converting precursor Z to molybdopterin, a key step in Moco biosynthesis (Reiss2000Genetics; Reiss2003Mutations).

MOCS2B interacts with MOCS2A to form an active MPT synthase, which is essential for Moco biosynthesis (Leimkühler2017Shared). MOCS2B also interacts with the Ada Two A containing (ATAC) histone acetyltransferase complex, influencing transcriptional regulation by decreasing the phosphorylation of PKR, which suppresses the phosphorylation of JNK and eIF2α. This interaction enhances the translation initiation of iron-responsive mRNA, linking Moco biosynthesis with iron homeostasis (Leimkühler2017Shared).

MOCS2 is part of the MPT synthase associating complex (MPTAC), which includes proteins such as MOCS3, DBN1, and CLNS1A. This complex regulates sulfur amino acid catabolism and prevents the accumulation of sulfite and reactive oxygen species (Suganuma2022Beyond). MOCS2 also interacts with MBIP, a component of the ATAC complex, which is essential for its regulatory functions (Leimkühler2017Shared).


## References


[1. (Hinderhofer2017Critical) Katrin Hinderhofer, Konstantin Mechler, Georg F. Hoffmann, Anette Lampert, William K. Mountford, and Markus Ries. Critical appraisal of genotype assessment in molybdenum cofactor deficiency. Journal of Inherited Metabolic Disease, 40(6):801–811, September 2017. URL: http://dx.doi.org/10.1007/s10545-017-0077-8, doi:10.1007/s10545-017-0077-8. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s10545-017-0077-8)

[2. (Leimkühler2017Shared) Silke Leimkühler. Shared function and moonlighting proteins in molybdenum cofactor biosynthesis. Biological Chemistry, 398(9):1009–1026, August 2017. URL: http://dx.doi.org/10.1515/hsz-2017-0110, doi:10.1515/hsz-2017-0110. This article has 27 citations and is from a peer-reviewed journal.](https://doi.org/10.1515/hsz-2017-0110)

[3. (Reiss2000Genetics) J. Reiss. Genetics of molybdenum cofactor deficiency. Human Genetics, 106(2):157–163, February 2000. URL: http://dx.doi.org/10.1007/s004399900223, doi:10.1007/s004399900223. This article has 21 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s004399900223)

[4. (JezelaStanek2020Proteins) Aleksandra Jezela-Stanek, Witold Blaz, Artur Gora, Malgorzata Bochenska, Katarzyna Kusmierska, and Jolanta Sykut-Cegielska. Proteins structure models in the evaluation of novel variant (c.472_477del) in the mocs2 gene. Diagnostics, 10(10):821, October 2020. URL: http://dx.doi.org/10.3390/diagnostics10100821, doi:10.3390/diagnostics10100821. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/diagnostics10100821)

[5. (Leimkühler2005Ten) Silke Leimkühler, Mathilde Charcosset, Philippe Latour, Claude Dorche, Soledad Kleppe, Fernando Scaglia, Irmina Szymczak, Petra Schupp, Rita Hahnewald, and Jochen Reiss. Ten novel mutations in the molybdenum cofactor genes mocs1 and mocs2 and in vitro characterization of a mocs2 mutation that abolishes the binding ability of molybdopterin synthase. Human Genetics, 117(6):565–570, July 2005. URL: http://dx.doi.org/10.1007/s00439-005-1341-9, doi:10.1007/s00439-005-1341-9. This article has 27 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s00439-005-1341-9)

[6. (Tofilo2023Live) Maria Tofilo, Natalia Voronova, Leila Nigmatullina, Elena Kuznetsova, Valeria Timonina, Bogdan Efimenko, Oybek Turgunkhujaev, Svetlana Avdeichik, Muhammad Ansar, Konstantin Popadin, Anastasia Kirillova, and Ilya Mazunin. Live birth of a healthy child in a couple with identical mtdna carrying a pathogenic c.471_477deltttaaaainsg variant in the mocs2 gene. Genes, 14(3):720, March 2023. URL: http://dx.doi.org/10.3390/genes14030720, doi:10.3390/genes14030720. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/genes14030720)

[7. (Reiss2003Mutations) Jochen Reiss and Jean L. Johnson. Mutations in the molybdenum cofactor biosynthetic genesmocs1, mocs2, andgeph. Human Mutation, 21(6):569–576, May 2003. URL: http://dx.doi.org/10.1002/humu.10223, doi:10.1002/humu.10223. This article has 115 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.10223)

[8. (Suganuma2022Beyond) Tamaki Suganuma. Beyond moco biosynthesis―moonlighting roles of moae and mocs2. Molecules, 27(12):3733, June 2022. URL: http://dx.doi.org/10.3390/molecules27123733, doi:10.3390/molecules27123733. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/molecules27123733)

[9. (Stoilov2002Defects) Peter Stoilov, Eran Meshorer, Marieta Gencheva, David Glick, Hermona Soreq, and Stefan Stamm. Defects in pre-mrna processing as causes of and predisposition to diseases. DNA and Cell Biology, 21(11):803–818, November 2002. URL: http://dx.doi.org/10.1089/104454902320908450, doi:10.1089/104454902320908450. This article has 61 citations and is from a peer-reviewed journal.](https://doi.org/10.1089/104454902320908450)

[10. (Arican2019The) Pinar Arican, Pinar Gencpinar, Ozgur Kirbiyik, Sema Bozkaya Yilmaz, Atilla Ersen, Ozgur Oztekin, and Nihal Olgac Dundar. The clinical and molecular characteristics of molybdenum cofactor deficiency due to mocs2 mutations. Pediatric Neurology, 99:55–59, October 2019. URL: http://dx.doi.org/10.1016/j.pediatrneurol.2019.04.021, doi:10.1016/j.pediatrneurol.2019.04.021. This article has 13 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.pediatrneurol.2019.04.021)